OPC 131461
Alternative Names: OPC-131461Latest Information Update: 28 Jun 2024
At a glance
- Originator Otsuka Pharmaceutical
- Class Heart failure therapies
- Mechanism of Action Vasopressin 1a receptor antagonists; Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiac oedema
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Cardiac-oedema(In volunteers) in Japan (PO, Suspension)
- 24 Nov 2022 Otsuka Pharmaceuticals completes a phase I trial in healthy adult male subjects in Japan (jRCT2071200061)
- 14 Nov 2022 Phase-II clinical trials in Cardiac oedema (In the elderly, Treatment-experienced, In adults) in Japan (PO) (NCT05615363)